Research & Innovation
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- St. Luke's
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Why Choose Us
-
Current Trials
- Back
- Current Trials
- Gastroenterology
- Gynecology
- Heart and Vascular
- Infectious Diseases
- Internal Medicine
- Neurosciences
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric / Esophageal Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- St. Luke's
- About Oncology Trials
- Glossary of Terms
- St. Luke's
- Orthopedics
- Pediatrics
- Pulmonary Medicine
- Trauma and Critical Care
- Wound Care
- St. Luke's
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- St. Luke's
- GME Data & Outcomes
- Post Doctoral Research
- Research Volunteer Program
- Institutional Review Board
- St. Luke's
- 1-866-STLUKES
Clinical Trials
Peerless_RCT (Cardiology)
The purpose of this research is to compare how FlowTriever and CDT devices work when treating pulmonary embolism, and to collect data about your pulmonary embolism treatment and follow-up. There is nothing investigational or experimental in your medical treatment if you participate in this study.
Study Coordinators
Kyle McFadden
484-658-1803
kyle.mcfadden@sluhn.org
Close
The purpose of this research is to compare how FlowTriever and CDT devices work when treating pulmonary embolism, and to collect data about your pulmonary embolism treatment and follow-up. There is nothing investigational or experimental in your medical treatment if you participate in this study.
Close
- Age ≥ 18 years
- Intervention planned to begin within 72 hours of the later of either: confirmed PE diagnosis; OR if transferring from another hospital, arrival at the treating hospital
- Symptom onset within 14 days of confirmed PE diagnosis
Close
Sanofi-Asthma ATLAS
A randomized, double-blind, placebo controlled study assessing the long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate to severe asthma
Study Coordinators
Margaret Clement
484-658-1799
Margaret.Clement@sluhn.org
Heather Herbold
484-658-1798
Heather.Herbold@sluhn.org
Close
The purpose of the study is to learn more about dupilumab (the study drug) when given over a longer duration (3 years) in patients with moderate to severe asthma that is not well controlled.
Close
- At least 18
- Patients with a physician diagnosis of asthma (according to Global Initiative for Asthma (GINA) 2021) for ≥12 months
- Treatment with medium to high dose inhaled corticosteroids (ICS) (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta-2 adrenergic receptor agonists (LABA), LTRA) with a stable dose ≥1 month
Close
Sanofi-COPD_AERIFY
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Study Coordinators
Margaret Clement
484-658-1799
Margaret.Clement@sluhn.org
Heather Herbold
484-658-1798
Heather.Herbold@sluhn.org
Close
The purpose of the study is to investigate the effect, safety, and tolerability of the study drug for the treatment of patients with COPD, who continue to have symptoms on current treatment, and who are in need of additional treatment to their current COPD management.
Close
- Age 40 to 85
- Diagnosed with COPD for at least 1 year with moderate to severe disease
- Former or current smoker
- At least one COPD exacerbation
- Controller COPD therapy
Close
Research
Interested in a
Clinical Trial?